NICE does not recommend cabazitaxel for people with hormone-refractory metastatic prostate cancer who have had docetaxel.
Why has NICE said this?
NICE looks at how well treatments work, and also at how well they work in relation to how much they cost the NHS. NICE applies special considerations to treatments that can extend the lives of people who are nearing the end of their life. Cabazitaxel does not provide enough benefit to patients to justify its high cost even when the special considerations were applied, so NICE did not recommend it.